A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Summary

This is a randomized, double-blind, placebo-controlled Phase Ib/IIa clinical study in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise and/or treated with irregular use of antidiabetic drugs to evaluate the safety, tolerability, pharmacokinetics and efficacy of GZR18 injection in adult subjects with T2DM. This study is divided into Part A and Part B, which are to be conducted simultaneously.

Timeline

Start

2022-06-29

Primary completion

2023-09-28

Completion

2023-09-28

Publications

• Liu M, Wang X, Li M, Yang E, Yang A, Yuan M, Dong R, Qin G, Liu P, Li C, Cao Y, Zhao J, Zhao L, Chen W. Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial. Cell Rep Med. 2026 Jun 19:102874. doi: 10.1016/j.xcrm.2026.102874. Online ahead of print.

Drugs

Indications